Blood pressure ‐ not measured · adults with a diagnosis of sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (machine tolerability outcomes) assessed as number of participants experiencing a blocked nose · adults with a diagnosis of sleep apnoea
Heated humidification + fixed CPAP may leads to lower adverse events (machine tolerability outcomes) assessed as number of… compared with fixed CPAP alone (low certainty).
1 finding from 1 review
Withdrawals (parallel group trials/first arm cross‐over trials) · adults with a diagnosis of OSA
Auto‐CPAP showed no clear difference in withdrawals (parallel group trials/first arm cross‐over trials) Median compared with fixed CPAP (moderate certainty).
1 finding from 1 review
Quality of life · adults with a diagnosis of OSA
1 finding from 1 review
AHI · adults with a diagnosis of OSA
1 finding from 1 review
Blood pressure · adults with a diagnosis of OSA
1 finding from 1 review
Adverse events (machine tolerability outcomes) · adults with a diagnosis of OSA
1 finding from 1 review
Machine usage Hours per night · adults with a diagnosis of sleep apnoea
1 finding from 1 review
All‐cause mortality · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause mortality compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).
1 finding from 1 review
Asthma‐related mortality · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
All‐cause mortality · children and adolescents with chronic asthma
1 finding from 1 review
Non‐fatal serious adverse events · children and adolescents with chronic asthma
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related mortality · children and adolescents with chronic asthma
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review
Linear growth velocity (cm/year) · children up to 18 years of age with persistent asthma
Effects of different inhaled corticosteroids on growth in children… may leads to higher linear growth velocity (cm/year) compared with beclomethasone (low certainty).
1 finding from 1 review
Linear growth velocity (cm/year) · children up to 18 years of age with persistent asthma
It is very uncertain whether effects of different inhaled corticosteroids on growth in children… changes linear growth velocity (cm/year) compared with budesonide (very low certainty).
1 finding from 1 review
Change in height · children up to 18 years of age with persistent asthma
Effects of different inhaled corticosteroids on growth in children… probably leads to higher change in height (cm) over a period of time compared with budesonide (moderate certainty).
1 finding from 1 review
Linear growth velocity (cm/year) · children up to 18 years of age with persistent asthma
Effects of different delivery devices on growth in children with… showed no clear difference in linear growth velocity (cm/year) compared with chlorofluorocarbon‐metered dose inhaler beclomethasone (low certainty).
1 finding from 1 review